ClinicalTrials.gg
Status unknownNCT03104010Updated Apr 7, 2017

A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD

A Phase 2 interventional study of Somatropin Injection in Adult Growth Hormone Deficiency, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Status unknown at 9 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Planned enrollment
10th of 60
180 · median 66
Started
2017
the only one that year
Phase 2
6 of 60
1 open now
Registered
53rd of 60
by date
Lead sponsor
10 of 60
Changchun GeneScience Pharmaceutical Co., Ltd.

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 10th largest by planned enrollment, is the only one that started in 2017, is one of 6 in phase 2, and was the 53rd registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

This study aims to explore the optimal dose of PEG-rhGH injection in the treatment of AGHD, preliminarily evaluate its safety and efficacy, to provide scientific and reliable evidence for the medication dosage in Phase 2 clinical study.

03

Conditions studied

  • Adult Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Before the treatment, the subject should be diagnosed as AGHD based on medical history, clinical symptoms, vital signs, insulin tolerance test and imagological examinations.

    • The subject is diagnosed as GHD during childhood and remains as GHD in adulthood, and the linear growth has completed: bone age (BA) ≥18 years old; or the AGHD patient who experiences paroxysm after 18 years old: such as patients who have experienced pituitary surgeries (2 years after pituitary adenoma surgery, 5 years after craniopharyngioma surgery and 12 months after other pituitary surgeries), traumatic brain injury (TBI), Sheehan syndrome, and etc..
    • The plasma GH concentration peak is \<5ng/ml in insulin tolerance test (ITT) (it's unnecessary to conduct ITT in the following conditions: anterior pituitary dysfunction, pituitary hormone deficiency (more than 3 hormones) and serum IGF-1 level below lower limit of normal value: i.e. -2 SD).
  • Age: 18-60 years old.
  • Patients with no history of GH treatment for more than one year.
  • (BMI): 18.5 kg/m2≤BMI≤30kg/m2.
  • When there is other hormones deficiency (such as , thyroid hormones and sex steroids), the subject should have received other hormone replacement therapies and the therapeutic dose shall be stable within 3 months before the enrolment.
  • The subject agrees to cooperate and complete the concerted trial procedures such as follow-ups, treatment plan and laboratory examinations, and sign the written .

Exclusion criteria

Exclusion Criteria:

  • Patients with serious heart diseases, including III or above, serious arrhythmia, unstable angina pectoris or myocardial infarction within the latest 6 months.
  • Patients with a history of ischemic cerebrovascular disease, febrile convulsion and epilepsy seizures.
  • Patients with carpal tunnel syndrome.
  • Patients with poor hypertension control (systolic pressure>140mmHg or diastolic pressure >90mmHg under treatment).
  • Patients with previous or present history of malignant tumor: two or more direct relatives within three generations have previous or present history of tumor.
  • Patients undergoing anti-depressive therapy, therapy, chemotherapy and radiotherapy (or with a history of radiotherapy).
  • Patients who have ever taken antiobesity drug within the latest 3 months.
  • Patients with serious infection.
  • Patients with consciousness disorders and mental diseases.
  • Subjects with impaired glucose regulation (IGR) (impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) ) or diabetes; patients with a family history of diabetes (direct relatives).
  • Subjects with abnormal liver and kidney functions ( > 2 times of value; calculated by MDRD formula \<60).
  • Subjects positive for , HBsAg or HBeAg in Hepatitis B virus tests.
  • Subjects with highly allergic constitution or allergy to proteins or productorits in this study.
  • Subjects who took part in other clinical trials within 3 months.
  • Patients with other mental or physical deficiencies that influence the evaluation of investigational product.
  • Pregnant or lactating women; females planning to get pregnant within one year.
  • Subjects whose tumor markers exceed the upper limit of normal range and the re-examination result is still high.
  • Other conditions which is unsuitable for the study in the opinion of the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    PEG-rhGH-1

    Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The first stage, 1-2mg/2-4mg, subcutaneous injection,weekly, 26 weeks.

    Drug: Somatropin Injection

  • Experimental
    PEG-rhGH-2

    Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The second stage (extension period study), maximum ≤4mg/w (24IU/w), 52 weeks.

    Drug: Somatropin Injection

Interventions

  • Recombinant human growth hormone injection, 15IU/5mg/3ml/bottle. The first stage , 0.17mg/d(0.5IU/d), subcutaneous injection ,daily, 26weeks. The second stage(extension period study), 0.17mg/d(0.5IU/d), maximum ≤0.68mg/d (2IU/w),52 weeks.

    Also known as: Recombinant human growth hormone injection

06

What researchers measure

Primary outcomes

  1. Fat mass change

    Change from baseline in fat mass (torso) (FM): FM at the end of treatment minus the baseline value

    Time frame: 52 weeks

Secondary outcomes

  1. Lean body mass change

    Change from baseline in lean body mass (LBM): LBM at the end of treatment minus the baseline value

    Time frame: 52 weeks

  2. Blood lipid change

    Change from baseline in blood lipid: blood lipid at the end of treatment minus the baseline value

    Time frame: 52 weeks

  3. Waist circumference change

    Change from baseline in waist circumference: waist circumference at the end of treatment minus the baseline value

    Time frame: 52 weeks

  4. Percentage of body fat change

    Change from baseline in the percentage of body fat: TBF at the end of treatment minus the baseline value

    Time frame: 52 weeks

  5. Cardiac function change

    Change from baseline in cardiac function: ejection fraction at the end of treatment minus the baseline value

    Time frame: 52 weeks

  6. Cardiac structure change

    Change from baseline in cardiac structure: left ventricular mass at the end of treatment minus the baselines value

    Time frame: 52 weeks

  7. IGF-1 change

    Changes from baseline in IGF-1: IGF-1 SDS at the end of treatment minus the baseline value

    Time frame: 52 weeks

  8. Grip change

    Changes from baseline in grip: grip at the end of treatment minus the baseline value, the method of assessment is measurement.

    Time frame: 52 weeks

  9. Quality of life change

    Changes from baseline in quality of life (QOL): changes in QOL scores before and after treatment

    Time frame: 52 weeks

  10. Waist-hip ratio change

    Changes from baseline in waist-hip ratio: changes of waist-hip ratio before and after treatment

    Time frame: 52 weeks

  11. Cardiac structure change

    Change from baseline in cardiac structure: carotid intima media thickness at the end of treatment minus the baselines value

    Time frame: 52 weeks

07

Study locations

1 of 9 sites recruiting
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Not yet recruiting
    • Songjun Zhang, Doctor · Contact
  • Heibei General Hospital
    Shijiazhuang, Hebei 050057, China
    Not yet recruiting
  • The Affiliated hospital of soochow University
    Suzhou, Jiangsu, China
    Not yet recruiting
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
    Not yet recruiting
    • Ling Jiang, Doctor · Contact
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
    Not yet recruiting
    • Zhenmei An, Doctor · Contact
  • The Second Affiliated Hospital of Zhejiang University school of medicine
    Hangzhou, Zhejiang, China
    Not yet recruiting
    • Wei Gu, Doctor · Contact
  • Peking Union Medical College Hospital
    Beijing, 100730, China
    Recruiting
    • Hui Pan, Doctor · Contact
  • Chongqing Three Gorges Central Hospital
    Chongqing, China
    Not yet recruiting
    • Yong Luo, Doctor · Contact
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
    Not yet recruiting
    • Wei Ren, Doctor · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2017; primary completion for Feb 2022, 58 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2017
First posted
Apr 7, 2017
StartEst.
Apr 2017
Primary completionEst.
Feb 2022
CompletionEst.
Sep 2022
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03104010
Collaborators
Peking Union Medical College Hospital, Peking University First Hospital, Hebei General Hospital, The Second Hospital of Hebei Medical University, Qilu Hospital of Shandong University, Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital of Soochow University, First Affiliated Hospital of Chongqing Medical University, Chongqing Three Gorges Central Hospital, West China Hospital
Responsible party
Sponsor
First posted
Apr 7, 2017
Start date
Apr 2017 (estimated)
Primary completion
Feb 2022 (estimated)
Completion
Sep 2022 (estimated)
Last update
Apr 7, 2017

Study contacts

Xiaohua Feng, MD
Contact
fengxiaohua@gensci-china.com
0431-85170552
Hui Pan, Doctor
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion